Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children

15 novembre 2019 mis à jour par: GlaxoSmithKline

Immunogenicity & Safety Study of GSK Biologicals' Meningococcal Vaccine GSK134612 When Co-Administered With GSK Biologicals' MMRV Vaccine (Priorix-Tetra™) in Healthy 12 to 23-Month-Old Children

The purpose of this study is to demonstrate, in 12-23 month old children, the non-inferiority of the meningococcal vaccine 134612 given with Priorix-Tetra.

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Aperçu de l'étude

Statut

Complété

Les conditions

Intervention / Traitement

Description détaillée

Open multicentre study with 4 treatment groups. Two groups will receive the 134612 vaccine with Priorix-Tetra either at the same or different visits followed by a second Priorix-Tetra vaccination at 84 days.

Two control groups will receive Priorix-Tetra and Meningitec at different visits followed by a second Priorix-Tetra vaccination at 84 days.

For all subjects, two blood samples will be taken: prior to and 42 days after the first vaccination. In a subset (30% of subjects in Groups A en C) from selected study centres: additional sample 42 days after second Priorix-Tetra dose.

Type d'étude

Interventionnel

Inscription (Réel)

1000

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

  • Finlande
      • Espoo, Finlande, 02100
        • GSK Investigational Site
      • Helsinki, Finlande, 00100
        • GSK Investigational Site
      • Helsinki, Finlande, 00930
        • GSK Investigational Site
      • Jarvenpaa, Finlande, 04400
        • GSK Investigational Site
      • Kotka, Finlande, 48600
        • GSK Investigational Site
      • Kuopio, Finlande, 70100
        • GSK Investigational Site
      • Lahti, Finlande, 15140
        • GSK Investigational Site
      • Oulu, Finlande, 90100
        • GSK Investigational Site
      • Pori, Finlande, 28100
        • GSK Investigational Site
      • Seinajoki, Finlande, 60100
        • GSK Investigational Site
      • Tampere, Finlande, 33100
        • GSK Investigational Site
      • Turku, Finlande, 20520
        • GSK Investigational Site
      • Vantaa, Finlande, 01300
        • GSK Investigational Site
      • Vantaa, Finlande, 01600
        • GSK Investigational Site

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

1 an à 1 an (Enfant)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.
  • A male or female between, and including, 12 and 23 months of age at the time of the vaccination.
  • Written informed consent obtained from the parent or guardian of the subject.
  • Free of obvious health problems as established by medical history and clinical examination before entering into the study.
  • Previously completed routine childhood vaccinations to the best of parents' or legal guardians' knowledge.

Exclusion Criteria:

  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the vaccine dose.
  • Planned administration/ administration of a vaccine not foreseen by the study protocol within one month before and 42 days after the first dose of vaccine(s).
  • Previous vaccination with meningococcal vaccine of serogroup A, C W and/or Y.
  • History of meningococcal disease.
  • Previous vaccination against measles, mumps, rubella, and/or varicella.
  • History of measles, mumps, rubella and/or varicella.
  • Known exposure to measles, mumps, rubella, varicella or zoster within 30 days prior to vaccination.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition (congenital or secondary), including human immunodeficiency virus (HIV) infection, based on medical history and physical examination.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, including neomycin.
  • Major congenital defects or serious chronic illness.
  • Acute disease at the time of enrolment.
  • Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: La prévention
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Nimenrix + Priorix-Tetra Group
Subjects received 1 dose of Nimenrix vaccine and 1 dose of Priorix-Tetra vaccine on Day 0 and a second dose of Priorix-Tetra vaccine on Day 84.
Biologique: Meningococcal vaccine GSK134612 (Nimenrix)
Single dose intramuscular injection
Biologique: Priorix-Tetra
2-dose subcutaneous injection
Expérimental: Nimenrix Group
Subjects received 1 dose of Nimenrix vaccine on Day 0 followed by 2 doses of Priorix-Tetra vaccine, respectively 42 and 84 days later.
Biologique: Meningococcal vaccine GSK134612 (Nimenrix)
Single dose intramuscular injection
Biologique: Priorix-Tetra
2-dose subcutaneous injection
Comparateur actif: Priorix-Tetra Group
Subjects received 1 dose of Priorix-Tetra vaccine on Day 0, 1 dose of Meningitec vaccine on Day 42 and a second dose of Priorix-Tetra vaccine on Day 84.
Biologique: Priorix-Tetra
2-dose subcutaneous injection
Biologique: Meningitec
Single dose intramuscular injection
Comparateur actif: Meningitec Group
Subjects received 1 dose of Meningitec vaccine on Day 0 followed by 2 doses of Priorix-Tetra vaccine, respectively 42 and 84 days later.
Biologique: Priorix-Tetra
2-dose subcutaneous injection
Biologique: Meningitec
Single dose intramuscular injection

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Number of Subjects With rSBA-MenC, rSBA-MenA, rSBA-MenW-135, rSBA-MenY Titers Greater Than or Equal to (≥) the Cut-off Values
Délai: 42 days after the first vaccine dose (Day 42)
The cut-off values for the rSBA titers were ≥ 1:8. The analysis was performed only on subjects receiving meningitis vaccination (Nimenrix) at Day 0.
42 days after the first vaccine dose (Day 42)
Number of Subjects With Anti-measles Antibody Concentrations ≥ the Cut-off Values
Délai: 42 days after the first vaccine dose (Day 42)
The cut-off values for anti-measles antibody concentrations were ≥ 150 milli-international units per milliliter (mIU/mL).
42 days after the first vaccine dose (Day 42)
Number of Subjects With Anti-mumps Antibody Concentrations ≥ the Cut-off Values
Délai: 42 days after the first vaccine dose (Day 42)
The cut-off values for anti-mumps antibody concentrations were ≥ 231 units per milliliter (U/mL).
42 days after the first vaccine dose (Day 42)
Number of Subjects With Anti-rubella Antibody Concentrations ≥ the Cut-off Values.
Délai: 42 days after the first vaccine dose (Day 42)
The cut-off values for anti-rubella antibody concentrations were ≥ 4 international units per milliliter (IU/mL).
42 days after the first vaccine dose (Day 42)
Number of Subjects With Anti-varicella Antibody Concentrations ≥ the Cut-off Values
Délai: 42 days after the first vaccine dose (Day 42)
The cut-off values for anti-varicella antibody concentrations were ≥ 1:4.
42 days after the first vaccine dose (Day 42)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers ≥ the Cut-off Values
Délai: Prior to vaccination (Day 0) and after the first vaccination dose (Day 42)
The cut-off values for the rSBA titers were ≥ 1:8 and ≥ 1:128 respectively. At pre-vaccination for all groups, half of the subjects were sera tested for rSBA-MenC while the other half was tested for rSBA-MenA, rSBA-MenW-135 and rSBA-MenY. At Post vaccination I (Day 42), all subjects from Nimenrix + Priorix-Tetra and Nimenrix groups were sera tested for each rSBA. For Meningitec and Priorix-Tetra groups, all subjects were tested for rSBA-MenC while half of subjects were tested for rSBA-MenA, rSBA-MenW-135 and rSBA-MenY.
Prior to vaccination (Day 0) and after the first vaccination dose (Day 42)
rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Antibody Titers
Délai: Prior to first vaccine dose (Day 0) and 42 days after the first vaccine dose (Day 42)
Antibody titers were expressed as geometric mean titers (GMTs). At pre-vaccination for all groups, half of the subjects were sera tested for rSBA-MenC while the other half were tested for rSBA-MenA, rSBA-MenW-135 and rSBA-MenY. At Post vaccination I (Day 42), all subjects from Nimenrix + Priorix-Tetra and Nimenrix groups were sera tested for each rSBA. For Meningitec and Priorix-Tetra groups, all subjects were tested for rSBA-MenC while half of subjects were tested for rSBA-MenA, rSBA-MenW-135 and rSBA-MenY.
Prior to first vaccine dose (Day 0) and 42 days after the first vaccine dose (Day 42)
Anti-PSA (Anti-polysaccharide A), Anti-PSC, Anti-PSW-135 and Anti-PSY Antibodies Concentrations ≥ the Cut-off Values
Délai: Prior to the first vaccine dose (Day 0) and 42 days after the first vaccine dose (Day 42)
Anti-PS antibody concentrations were given as geometric mean concentrations (GMCs) and expressed as microgram per milliliter (μg/mL). At pre-vaccination (Day 0) and Post-vaccination I (Day 42), a quarter of the subjects were tested for anti-PSC and another quarter for anti-PSA, anti-PSW-135 and anti-PSY.
Prior to the first vaccine dose (Day 0) and 42 days after the first vaccine dose (Day 42)
Number of Subjects With Anti-PSA, Anti-PSC, Anti-PSW-135 and Anti-PSY Antibodies Concentrations ≥ the Cut-off Values
Délai: Prior to first vaccine dose (Day 0) and 42 days after the first vaccine dose (Day 42)
The cut-off values for anti-PS antibody concentrations were ≥ 0.3 μg/mL and ≥ 2.0 μg/mL respectively. At pre-vaccination (Day 0) and Post-vaccination I (Day 42), a quarter of the subjects were tested for anti-PSC and another quarter for anti-PSA, anti-PSW-135 and anti-PSY.
Prior to first vaccine dose (Day 0) and 42 days after the first vaccine dose (Day 42)
Number of Subjects With hSBA-MenA (Meningococcal Polysaccharide A Serum Bactericidal Antibodies Using Human Complement), hSBA-MenC, hSBA-MenW-135 and hSBA-MenY Titers ≥ the Cut-off Values
Délai: Prior to first vaccine dose (Day 0) and 42 days after the first vaccine dose (Day 42)
The cut-off values for hSBA antibody titers were ≥ 1:4 and ≥ 1:8 for Nimenrix + Priorix-Tetra group, Nimenrix group, Meningitec group and Pooled group (Nimenrix + Priorix-Tetra and Nimenrix groups), respectively. The analysis was performed only on subjects receiving meningitis vaccination (Nimenrix) at Day 0.
Prior to first vaccine dose (Day 0) and 42 days after the first vaccine dose (Day 42)
hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY Antibody Titers
Délai: Prior to first vaccine dose (Day 0) and 42 days after the first vaccine dose (Day 42)
Anti-hSBA antibody titers were expressed as geometric mean titers (GMTs) for Nimenrix + Priorix-Tetra group, Nimenrix group, Meningitec group and Pooled group (Nimenrix + Priorix-Tetra and Nimenrix groups), respectively. The analysis was performed only on subjects receiving meningitis vaccination (Nimenrix) at Day 0.
Prior to first vaccine dose (Day 0) and 42 days after the first vaccine dose (Day 42)
Anti-measles Antibody Concentrations
Délai: 42 days after the first vaccine dose (Day 42)
Anti-measles antibody concentrations were given as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL) in all groups.
42 days after the first vaccine dose (Day 42)
Anti-measles Antibody Concentrations
Délai: 42 days after the second Priorix-Tetra vaccine dose (Day 126)
Anti-measles antibody concentrations were given as geometric mean concentrations (GMCs) and expressed in mIU/mL in a subset (30%) of the Nimenrix + Priorix-Tetra and Priorix-Tetra groups only. The analysis was performed only on subjects receiving varicella vaccination (Priorix-Tetra) at Day 0.
42 days after the second Priorix-Tetra vaccine dose (Day 126)
Anti-mumps Antibody Concentrations
Délai: 42 days after the first vaccine dose (Day 42)
Anti-mumps antibody concentrations were given as geometric mean concentrations (GMCs) and expressed in units per milliliter (U/mL) in all groups.
42 days after the first vaccine dose (Day 42)
Anti-mumps Antibody Concentrations
Délai: 42 days after the second Priorix-Tetra vaccine dose (Day 126)
Anti-mumps antibody concentrations were given as geometric mean concentrations (GMCs) and expressed in U/mL in a subset (30%) of the Nimenrix + Priorix-Tetra and Priorix-Tetra groups only. The analysis was performed only on subjects receiving varicella vaccination ( Priorix-Tetra) at Day 0.
42 days after the second Priorix-Tetra vaccine dose (Day 126)
Anti-rubella Antibody Concentrations
Délai: 42 days after the first vaccine dose (Day 42)
Anti-rubella antibody concentrations were given as geometric mean concentrations (GMCs) and expressed in international units per millilier (IU/mL) in all groups.
42 days after the first vaccine dose (Day 42)
Anti-rubella Antibody Concentrations
Délai: 42 days after the second Priorix-Tetra vaccine dose (Day 126)
Anti-rubella antibody concentrations were given as geometric mean concentrations (GMCs) and expressed in IU/mL in a subset (30%) of the Nimenrix + Priorix-Tetra and Priorix-Tetra groups only. The analysis was performed only on subjects receiving varicella vaccination (Priorix-Tetra) at Day 0.
42 days after the second Priorix-Tetra vaccine dose (Day 126)
Anti-varicella Antibody Titers
Délai: 42 days after the first vaccine dose (Day 42)
Anti-varicella antibody titers were given as geometric mean titers (GMTs) for all groups.
42 days after the first vaccine dose (Day 42)
Anti-varicella Antibody Titers
Délai: 42 days after the second Priorix-Tetra vaccine dose (Day 126)
Anti-varicella antibody titers were given as geometric mean titers (GMTs) in a subset (30%) of the Nimenrix + Priorix-Tetra and Priorix-Tetra groups only. The analysis was performed only on subjects receiving varicella vaccination ( Priorix-Tetra) at Day 0.
42 days after the second Priorix-Tetra vaccine dose (Day 126)
Number of Subjects Reporting Solicited Local Symptoms Specific for Priorix-Tetra Vaccination
Délai: During the 4-day (Days 0-3) after vaccination with first dose of Priorix-Tetra vaccine at Day 0
Solicited local symptoms assessed were pain, redness and swelling for the Nimenrix + Priorix-Tetra Group and Priorix-Tetra Group, respectively. The analysis was performed only on subjects receiving varicella vaccination (Priorix-Tetra) at Day 0.
During the 4-day (Days 0-3) after vaccination with first dose of Priorix-Tetra vaccine at Day 0
Number of Subjects Reporting Solicited Local Symptoms After Nimenrix or Meningitec Vaccination at Day 0
Délai: During the 4-day (Days 0-3) after vaccination with Nimenrix or Meningitec at Day 0
Solicited local symptoms assessed were pain, redness and swelling for the Nimenrix + Priorix-Tetra Group, Nimenrix Group and Meningitec Group, respectively. The analysis was performed only on subjects receiving meningitis vaccination (Priorix-Tetra) at Day 0.
During the 4-day (Days 0-3) after vaccination with Nimenrix or Meningitec at Day 0
Number of Subjects Reporting Solicited General Symptoms
Délai: During the 4-day (Days 0-3) follow-up period after first vaccination dose in all groups
Solicited general symptoms assessed were drowsiness, fever (measured rectally and temperature ≥ 38.0°C ), irritability and loss of appetite, Meningismus, Parotiditis and Rash.
During the 4-day (Days 0-3) follow-up period after first vaccination dose in all groups
Number of Subjects With Priorix-Tetra - Specific Solicited General Symptoms
Délai: During the 43-day (Days 0-42) after first vaccination dose
Solicited general symptoms assessed were fever (measured rectally and temperature ≥ 38.0°C ), Meningismus, Parotiditis and Rash.
During the 43-day (Days 0-42) after first vaccination dose
Number of Subjects Reporting Specific Adverse Events (AEs)
Délai: From Day 0 up to Month 6 after first vaccine dose
Specific AEs include: rash, New Onset of Chronic Illness(es) (NOCI), and/or conditions prompting emergency room (ER) visits or non-routine physician office visits.
From Day 0 up to Month 6 after first vaccine dose
Number of Subjects Reporting Unsolicited Symptoms
Délai: During the 43-day (Days 0-42) post Dose 1 vaccination period
Unsolicited symptom covers any symptom reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
During the 43-day (Days 0-42) post Dose 1 vaccination period
Number of Subjects Reporting Unsolicited Symptoms
Délai: During the 43-day (Days 0-42) follow-up period after each vaccination
Unsolicited symptom covers any symptom reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
During the 43-day (Days 0-42) follow-up period after each vaccination
Number of Subjects Reporting Serious Adverse Events (SAEs)
Délai: From Day 0 up to Month 6 after vaccination
SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization, result in disability/ incapacity or are a congenital anomaly/ birth defect in the offspring of a study subject.
From Day 0 up to Month 6 after vaccination

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

GlaxoSmithKline

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Liens utiles

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

5 juin 2007

Achèvement primaire (Réel)

26 février 2008

Achèvement de l'étude (Réel)

26 mars 2008

Dates d'inscription aux études

Première soumission

15 mai 2007

Première soumission répondant aux critères de contrôle qualité

15 mai 2007

Première publication (Estimation)

16 mai 2007

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

18 novembre 2019

Dernière mise à jour soumise répondant aux critères de contrôle qualité

15 novembre 2019

Dernière vérification

1 novembre 2019

Plus d'information

Termes liés à cette étude

Mots clés

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • 109670
  • 2006-006580-23 (Numéro EudraCT)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

Délai de partage IPD

IPD is available via the Clinical Study Data Request site (click on the link provided below)

Critères d'accès au partage IPD

Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE
  • CIF
  • RSE

Données/documents d'étude

  1. Formulaire de rapport de cas annoté
    Identifiant des informations: 109670
    Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register
  2. Formulaire de consentement éclairé
    Identifiant des informations: 109670
    Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register
  3. Plan d'analyse statistique
    Identifiant des informations: 109670
    Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register
  4. Protocole d'étude
    Identifiant des informations: 109670
    Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register
  5. Rapport d'étude clinique
    Identifiant des informations: 109670
    Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register
  6. Ensemble de données de participant individuel
    Identifiant des informations: 109670
    Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register
  7. Spécification du jeu de données
    Identifiant des informations: 109670
    Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

Essais cliniques sur Infections méningococciques

Rechercher des essais similaires

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

CROs by country

CROs in Saudi Arabia

Conditions

Maladies rares

Interventions en matière de drogue

Compléments alimentaires

Commanditaire / collaborateurs

Emplacements

3
S'abonner